SLC1A5 and metabolic disease: Corrigendum: Novel chemical scaffolds to inhibit the neutral amino acid transporter B&lt;sup&gt;0&lt;/sup&gt;AT1 (SLC6A19), a potential target to treat metabolic diseases.